N E W S  A R C H I V E  

CONFERENCE NEWS:

Stephen Frye to present at 36th Annual UNC Lineberger Comprehensive Cancer Center Symposium, April 25-26, 2012.  

Stephen Frye to present in the Drug Discovery Centers section of the October 18, 2011 Baltimore conference

Drug Discovery in Academia - The New Paradigm for Drug Discovery

Conference Flyer

RESEARCH NEWS

First Epigenetic Probe Discovered at UNC

G9a/GLP selective methyltransferase chemical probe UNC0638 released June 1, 2010.

FUNDING & COLLABORATIONS

Drug Discovery Contracts awarded for Two Cancer Targets (July 2010)

As part of a national effort to accelerate the identification and testing of new anticancer drugs, SAIC-Frederick, Inc., a prime contractor to the National Cancer Institute has awarded two contracts totaling $2.4 million to two teams of UNC scientists to initiate the discovery of drugs for the treatment of childhood leukemia and brain tumors.

Stephen Frye, PhD, professor of medicinal chemistry and director of the UNC Center for Integrative Chemical Biology and Drug Discovery in the UNC Eshelman School of Pharmacy, is principal investigator. Frye is also a member of UNC Lineberger Comprehensive Cancer Center. The two centers are collaborating on both projects.    Read More

William Janzen receives small grant from National Institute on Drug Abuse for High-throughput Screening for the Discovery of Novel Scaffolds that Antagonize Methylated Histone Recognition. (1R03-DA030553)

CICBDD to collaborate on NIH Transformative R01 grant awarded to Dr. Mark Zylka, Asociate Professor of Cell and Molecular Biology, UNC School of Medicine.  

This research will focus on harnessing particular enzymes found on the membrane of pain-sensing neurons and determining if these enzymes can be used alone or in combination to treat acute and chronic pain. In collaboration with a group headed by Stephen V. Frye, Ph.D. at the Eshelman School of Pharmacy, Zylka will use medicinal chemistry to synthesize “prodrugs,” pharmacologically inactive compounds that convert to the active form of the drug within the body.

 OTHER ITEMS

• Frye Leads UNC Team Selected for NCI Drug-Discovery Initiative
• Stephen Frye / UNC help found NC Drug Discovery Center of Innovation

 Jian Jin to lead project funded by NIMH as supplement to U19 grant to collaborator Bryan Roth, PI (3U19MH082441-03S1) Functional Selectivity: A Novel Approach for CNS Drug  Discovery 

The overall objectives of this project are to create novel dopamine D2 ligands with unprecedented patterns of functional selectivity for elucidating the key signal transduction pathways essential for antipsychotic efficacy, and to discover novel, functionally selective antipsychotic drug candidates that are safer and more effective than existing antipsychotics. 

Stephen Frye is awarded NIH Challenge Grant from the National Institute of General Medical Science for Discovery of Small Molecule MBT Domain Antagonists. (1RC1GM90732)

The primary objective of this research is to develop potent antagonists of methyl-lysine recognition by human and Drosophila MBT domain containing proteins in order to permit exploration of the biological consequences of blocking this recognition in cell based and in vivo models with relevance to normal and disease biology.